Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.

Thirty-six consecutive patients with breast cancer and liver metastases with abnormal liver biochemistry were treated with epirubicin 25 mg m-2 i.v. weekly. No dose modification was made for abnormal liver biochemistry, but dose intensity was adjusted by delaying treatment according to myelosuppress...

Descripción completa

Detalles Bibliográficos
Autores principales: Twelves, C. J., O'Reilly, S. M., Coleman, R. E., Richards, M. A., Rubens, R. D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247276/
https://www.ncbi.nlm.nih.gov/pubmed/2605102
_version_ 1782150946971713536
author Twelves, C. J.
O'Reilly, S. M.
Coleman, R. E.
Richards, M. A.
Rubens, R. D.
author_facet Twelves, C. J.
O'Reilly, S. M.
Coleman, R. E.
Richards, M. A.
Rubens, R. D.
author_sort Twelves, C. J.
collection PubMed
description Thirty-six consecutive patients with breast cancer and liver metastases with abnormal liver biochemistry were treated with epirubicin 25 mg m-2 i.v. weekly. No dose modification was made for abnormal liver biochemistry, but dose intensity was adjusted by delaying treatment according to myelosuppression. The UICC overall response rate according to UICC criteria was 11/36 (30%) and median response duration was 27 weeks. Liver biochemistry improved in a further seven patients. Treatment was well tolerated. Epirubicin given in this way is effective in patients with breast cancer and liver metastases. An initial deterioration in liver biochemistry may occur before there is a response to epirubicin.
format Text
id pubmed-2247276
institution National Center for Biotechnology Information
language English
publishDate 1989
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22472762009-09-10 Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. Twelves, C. J. O'Reilly, S. M. Coleman, R. E. Richards, M. A. Rubens, R. D. Br J Cancer Research Article Thirty-six consecutive patients with breast cancer and liver metastases with abnormal liver biochemistry were treated with epirubicin 25 mg m-2 i.v. weekly. No dose modification was made for abnormal liver biochemistry, but dose intensity was adjusted by delaying treatment according to myelosuppression. The UICC overall response rate according to UICC criteria was 11/36 (30%) and median response duration was 27 weeks. Liver biochemistry improved in a further seven patients. Treatment was well tolerated. Epirubicin given in this way is effective in patients with breast cancer and liver metastases. An initial deterioration in liver biochemistry may occur before there is a response to epirubicin. Nature Publishing Group 1989-12 /pmc/articles/PMC2247276/ /pubmed/2605102 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Twelves, C. J.
O'Reilly, S. M.
Coleman, R. E.
Richards, M. A.
Rubens, R. D.
Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
title Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
title_full Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
title_fullStr Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
title_full_unstemmed Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
title_short Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
title_sort weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247276/
https://www.ncbi.nlm.nih.gov/pubmed/2605102
work_keys_str_mv AT twelvescj weeklyepirubicinforbreastcancerwithlivermetastasesandabnormalliverbiochemistry
AT oreillysm weeklyepirubicinforbreastcancerwithlivermetastasesandabnormalliverbiochemistry
AT colemanre weeklyepirubicinforbreastcancerwithlivermetastasesandabnormalliverbiochemistry
AT richardsma weeklyepirubicinforbreastcancerwithlivermetastasesandabnormalliverbiochemistry
AT rubensrd weeklyepirubicinforbreastcancerwithlivermetastasesandabnormalliverbiochemistry

Ejemplares similares